NCT02401243 - Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients | Biotech Hunter

Enrollment

253

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

INSULIN GLARGINE (U300)

"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"

Trial Locations (25)

V2S3N5

Investigational Site Number 124001, Abbotsford

L6T4V3

Investigational Site Number 124013, Brampton

Unknown

Investigational Site Number 124008, Burlington

Investigational Site Number 124021, Hamilton

Investigational Site Number 124003, Oshawa

Investigational Site Number 124012, Québec

V5G1T4

Investigational Site Number 124024, Burnaby

L9Y1W3

Investigational Site Number 124015, Collingwood

N0N 1G0

Investigational Site Number 124025, Corunna

M9V4V4

Investigational Site Number 124019, Etobicoke

H7T 2P5

Investigational Site Number 124011, Laval

G6W5M6

Investigational Site Number 124005, Lévis

N5W 6A2

Investigational Site Number 124018, London

G1W4R4

Investigational Site Number 124010, Québec

N7T 4R9

Investigational Site Number 124007, Sarnia

S7K 3H3

Investigational Site Number 124002, Saskatoon

J1G5K2

Investigational Site Number 124023, Sherbrooke

K7A4W8

Investigational Site Number 124009, Smiths Falls

N7G1Y7

Investigational Site Number 124017, Strathroy

M8V3X8

Investigational Site Number 124020, Toronto

V5Z1M9

Investigational Site Number 124006, Vancouver

V6J1S3

Investigational Site Number 124026, Vancouver

V8V4H1

Investigational Site Number 124004, Victoria

R2V4W3

Investigational Site Number 124014, Winnipeg

R3E 3P4

Investigational Site Number 124016, Winnipeg